Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
GLOBETECH PUBLISHING LLC

New Ultrasound Applications Detects Early Response to Pancreatic Cancer Therapy

By Medimaging International staff writers
Posted on 06 Mar 2013
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
In a recent study, investigators utilized dynamic contrast enhanced-perfusion imaging (DCE-PI) and ultrasonic molecular imaging (USMI) to gauge response to therapy for pancreatic cancer.

The research was published in the January 2013 issue journal Technology in Cancer Research and Treatment. Paul Dayton, PhD, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center (Chapel Hill, USA), and senior author of the study, said, “What we found is that using two noninvasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new noninvasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person’s treatment to improve outcomes.”

Dr. Dayton, a UNC associate professor of biomedical engineering, worked with Jen Jen Yeh, M.D, an associate professor of surgery and pharmacology, to assess the imaging technologies on human pancreatic cancer in a preclinical model. Both investigators are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to depict noninvasively the biologic processes at the cellular and molecular levels. It accomplishes this with the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a conventional ultrasound system to identify signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a technique used noninvasively to track the blood flow in the microcirculation. Because growing tumors require abnormally increased blood flow, alterations in blood vessel structure or density can provide data regarding tumor malignancy. The researchers employed a drug that suppresses a protein specific to tumors. They then used the imaging applications to gauge the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The findings indicated that USMI was able to detect molecular signs of tumor response to therapy after only two days.

A change in blood flow in the tumor was seen to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Therefore, these modalities revealed a substantial improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

The contrast agents for USMI currently in clinical trials in Europe for cancer imaging, however, they are not yet available in the United States.

Related Links:
University of North Carolina Lineberger Comprehensive Cancer Center



Channels

Radiography

view channel

Pediatric Radiation Dose Reduction Key Factor in Selection of DR Systems

X-Ray dose reduction potential was a key factor in the decision of the Washington DC (USA) metropolitan area Children’s National Health System to install new Direct Radiography (DR) systems. The priority of Children’s National Health System was to ensure that pediatric patients would receive the lowest possible dose... Read more

MRI

view channel
Image: The Micronor M303 Encoding Sensor with A/B Quadrature Pulse Train Background (Photo courtesy of Micronor).

World’s First MRI-Safe Linear Encoder for Medical Applications Announced

A company specialized in producing fiber optic kinetic sensors, has developed a first-of-a-kind passive, optical, non-electronic, high-precision encoder for use in medical Magnetic Resonance Imaging (MRI).... Read more

Nuclear medicine

view channel

Hybrid Scanner Using Five Molecular Imaging Techniques Under Development

Scientists are developing a new molecular, preclinical hybrid imaging system to help find new drugs and to advance imaging research. The scanner was presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI; Reston, Virginia, USA), and consists of a window for tissue observation,... Read more

General/Advanced Imaging

view channel

FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System

The US Food and Drug Administration (FDA) has provided Investigational Device Exemption (IDE) approval for company to trial a new image-guided cancer surgery system for intraoperative imaging of breast cancer. The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell... Read more

Imaging IT

view channel
Image: Siemens radiation therapy Syngo.via image suite (Photo courtesy of Siemens Healthcare).

New Version of Syngo.via Supports Treatment Decision in Oncology

Siemens Healthcare has released a new version of oncology diagnostics software that helps physicians plan the best course of treatment for cancer patients. Cancer treatment requires comprehensive diagnostics,... Read more

Industry News

view channel
Image: The Westchester Medical Center in Valhalla, NY, USA (Photo courtesy of Business Wire).

Philips to Provide Multi-Year USD 500 Million in Healthcare Services in the USA

Royal Philips (Amsterdam, the Netherlands) and the Westchester Medical Center Health Network (WMCHealth; Valhalla, NY, USA) have announced USD 500 million multi-year partnership. Philips will provide... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.